Ars Technica
Oct 21, 2026
The $15 billion ad-powered AI startup your doctor may already be using
OpenEvidence is booming despite questions about accuracy and ads.
OpenEvidence is booming despite questions about accuracy and ads.
| Winners | Losers |
|---|---|
| BRZE $45.57 +51.70% | TSEM $183.78 -8.25% |
| SLS $11.98 +14.20% | LGN $41.23 -6.74% |
| EQPT $15.60 +11.83% | DXPE $170.55 -4.72% |
| HAS $109.52 +11.20% | MXL $73.51 -4.67% |
| NESR $21.09 +11.12% | SMTC $136.20 -4.23% |
| Winners | Losers |
|---|---|
| LION $12.15 +14.41% | SE $80.43 -9.09% |
| KVYO $19.61 +11.93% | DPC $29.12 -8.91% |
| TLK $11.64 +11.39% | GM $77.09 -6.84% |
| EFX $176.54 +11.33% | MLI $56.81 -6.59% |
| SPHR $112.84 +9.67% | AERO $14.88 -6.36% |
Andrew Hauser says central bank faces ‘hard choices’ as it looks to balance risks of entrenched inflation with desire to protect labour marketGet our breaking news email, free app or daily news podcastThe chance of a fifth interest rate hike on Melbourne Cup day has jumped after Andrew Hauser, the …